Prestige Wealth Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.87K | Sell |
34
-42
| -55% | -$2.31K | ﹤0.01% | 746 |
|
|
2025
Q1 | $5.37K | Buy |
76
+42
| +124% | +$2.97K | ﹤0.01% | 549 |
|
|
2024
Q4 | $2.24K | Sell |
34
-25
| -42% | -$1.64K | ﹤0.01% | 760 |
|
|
2024
Q3 | $4.15K | Buy |
59
+25
| +74% | +$1.76K | ﹤0.01% | 636 |
|
|
2024
Q2 | $2.8K | Sell |
34
-18
| -35% | -$1.48K | ﹤0.01% | 651 |
|
|
2024
Q1 | $4.54K | Sell |
52
-64
| -55% | -$5.59K | ﹤0.01% | 594 |
|
|
2023
Q4 | $11.2K | Buy |
116
+6
| +5% | +$579 | ﹤0.01% | 425 |
|
|
2023
Q3 | $9.73K | Sell |
110
-27
| -20% | -$2.39K | ﹤0.01% | 440 |
|
|
2023
Q2 | $11.9K | Hold |
137
| – | – | ﹤0.01% | 434 |
|
|
2023
Q1 | $13.3K | Buy |
137
+7
| +5% | +$681 | ﹤0.01% | 390 |
|
|
2022
Q4 | $13.5K | Buy |
130
+9
| +7% | +$931 | ﹤0.01% | 404 |
|
|
2022
Q3 | $11K | Sell |
121
-100
| -45% | -$9.09K | ﹤0.01% | 402 |
|
|
2022
Q2 | $19K | Buy |
221
+72
| +48% | +$6.19K | 0.01% | 335 |
|
|
2022
Q1 | $11K | Hold |
149
| – | – | ﹤0.01% | 438 |
|
|
2021
Q4 | $13K | Hold |
149
| – | – | ﹤0.01% | 438 |
|
|
2021
Q3 | $11K | Buy |
149
+12
| +9% | +$886 | ﹤0.01% | 462 |
|
|
2021
Q2 | $11K | Buy |
137
+16
| +13% | +$1.29K | ﹤0.01% | 451 |
|
|
2021
Q1 | $9K | Sell |
121
-19
| -14% | -$1.41K | ﹤0.01% | 488 |
|
|
2020
Q4 | $12K | Buy |
140
+73
| +109% | +$6.26K | ﹤0.01% | 421 |
|
|
2020
Q3 | $5K | Sell |
67
-60
| -47% | -$4.48K | ﹤0.01% | 531 |
|
|
2020
Q2 | $16K | Buy |
127
+64
| +102% | +$8.06K | 0.01% | 361 |
|
|
2020
Q1 | $5K | Buy |
+63
| New | +$5K | ﹤0.01% | 482 |
|
|
2019
Q1 | – | Sell |
-127
| Closed | -$11K | – | 574 |
|
|
2018
Q4 | $11K | Buy |
+127
| New | +$11K | 0.01% | 410 |
|